Skip to main
  1. Stocks
  2. Lakefront Biotherapeutics
  3. Forecast
LKFT

Lakefront Biotherapeutics (LKFT) Stock Forecast & Price Target

Lakefront Biotherapeutics (LKFT) Analyst Ratings

Based on 2 analyst ratings
Hold
Strong Buy 0%
Buy 50%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Lakefront Biotherapeutics is attractive because its lead asset, gamgertamig, has shown rapid and durable B-cell depletion with a differentiated safety profile that could outclass CAR-T approaches in rare autoimmune diseases. The company also has substantial financial flexibility, reporting €2.23 billion in cash/equivalents and expected year-end cash of €1.975-2.050 billion, while lower-than-expected R&D of €26 million and SG&A of €23 million reflect a wind-down in cell therapy spending. With dose-optimization data expected in 2H26 and registrational programs expected in 2027, the prospect of meaningful royalty revenue, potential basket-study expansion, and limited downside from its cash-rich balance sheet supports a constructive fundamental view.

Bears say

Lakefront Biotherapeutics is facing a weakened fundamental outlook because its '3667 lupus program failed at both the 32-week primary endpoint and 48-week secondary endpoint, forcing management to halt further development in SLE and leaving the asset’s strategic value uncertain despite positive dermatomyositis data. The investment case now depends heavily on gamgertamig and three undisclosed preclinical assets from Ouro, but detailed data are limited, registrational studies are only expected to start next year, and broader autoimmune basket studies are not expected until later this year/2027, creating a long visibility gap. If the company cannot secure competitive assets or out-license '3667, and if competitive dynamics constrain commercialization, the pipeline may not support sufficient future value creation, especially given the ongoing need to build a novel pipeline at attractive valuations.

Lakefront Biotherapeutics (LKFT) has been analyzed by 2 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 50% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lakefront Biotherapeutics and is not a guaranteed prediction by Public.com or investment advice.

Lakefront Biotherapeutics (LKFT) Analyst Forecast & Price Prediction

Get the latest Lakefront Biotherapeutics (LKFT) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Lakefront Biotherapeutics (LKFT)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lakefront Biotherapeutics (LKFT) Forecast

Analysts have given Lakefront Biotherapeutics (LKFT) a Hold based on their latest research and market trends.

According to 2 analysts, Lakefront Biotherapeutics (LKFT) has a Hold consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $36, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $36, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lakefront Biotherapeutics (LKFT)


Lakefront Biotherapeutics (LKFT) Analyst Forecast & Price Prediction

Get the latest Lakefront Biotherapeutics (LKFT) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Lakefront Biotherapeutics (LKFT)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover LKFT stock data and trends